The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient reported outcomes (PRO) results for prophylactic effect of dexamethasone on regorafenib-related fatigue and/or malaise: a randomized, placebo-controlled, double-blind clinical study in patients with unresectable metastatic colorectal cancer: KSCC1402/HGCSG1402.
 
Mototsugu Shimokawa
Consulting or Advisory Role - Sysmex
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Takuhiro Yamaguchi
Consulting or Advisory Role - CAC Croit Corporation; Chugai Pharma; Japan Tobacco Inc; Kowa; Ono Pharmaceutical; TSUMURA & CO.
Research Funding - A2 Healthcare (Inst); AC Medical (Inst); CAC Croit Corporation (Inst); Facet Biotech (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Kyowa Hakko Kirin (Inst); Luminary Medical (Inst); Medidata Solutions, Inc (Inst); Ono Pharmaceutical (Inst)
 
Hiroaki Tanioka
No Relationships to Disclose
 
Yuji Miyamoto
No Relationships to Disclose
 
Akihito Tsuji
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
 
Masako Asayama
No Relationships to Disclose
 
Takeshi Shiraishi
No Relationships to Disclose
 
Satoshi Yuki
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Masahito Kotaka
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Akitaka Makiyama
No Relationships to Disclose
 
Takayuki Shimose
No Relationships to Disclose
 
Satohiro Masuda
No Relationships to Disclose
 
Yoshito Komatsu
Honoraria - Bayer; Novartis; Pfizer
Speakers' Bureau - Bayer; Chugai Pharma; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Bayer; Chugai Pharma; Lilly; MSD; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Hiroshi Saeki
No Relationships to Disclose
 
Yasunori Emi
No Relationships to Disclose
 
Hideo Baba
Speakers' Bureau - Lilly; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Johnson & Johnson (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Yakult Honsha (Inst)
 
Yoshihiko Maehara
No Relationships to Disclose